1. Home
  2. RCKT vs KFS Comparison

RCKT vs KFS Comparison

Compare RCKT & KFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCKT
  • KFS
  • Stock Information
  • Founded
  • RCKT 1999
  • KFS 1989
  • Country
  • RCKT United States
  • KFS United States
  • Employees
  • RCKT N/A
  • KFS N/A
  • Industry
  • RCKT Biotechnology: Pharmaceutical Preparations
  • KFS Property-Casualty Insurers
  • Sector
  • RCKT Health Care
  • KFS Finance
  • Exchange
  • RCKT Nasdaq
  • KFS Nasdaq
  • Market Cap
  • RCKT 328.6M
  • KFS 417.8M
  • IPO Year
  • RCKT N/A
  • KFS 1996
  • Fundamental
  • Price
  • RCKT $3.28
  • KFS $14.37
  • Analyst Decision
  • RCKT Buy
  • KFS
  • Analyst Count
  • RCKT 13
  • KFS 0
  • Target Price
  • RCKT $12.96
  • KFS N/A
  • AVG Volume (30 Days)
  • RCKT 6.0M
  • KFS 69.0K
  • Earning Date
  • RCKT 08-07-2025
  • KFS 08-07-2025
  • Dividend Yield
  • RCKT N/A
  • KFS N/A
  • EPS Growth
  • RCKT N/A
  • KFS N/A
  • EPS
  • RCKT N/A
  • KFS N/A
  • Revenue
  • RCKT N/A
  • KFS $119,287,000.00
  • Revenue This Year
  • RCKT N/A
  • KFS N/A
  • Revenue Next Year
  • RCKT $108.43
  • KFS N/A
  • P/E Ratio
  • RCKT N/A
  • KFS N/A
  • Revenue Growth
  • RCKT N/A
  • KFS 12.05
  • 52 Week Low
  • RCKT $2.19
  • KFS $7.06
  • 52 Week High
  • RCKT $22.01
  • KFS $16.80
  • Technical
  • Relative Strength Index (RSI)
  • RCKT 51.17
  • KFS 54.71
  • Support Level
  • RCKT $2.88
  • KFS $13.96
  • Resistance Level
  • RCKT $3.74
  • KFS $14.36
  • Average True Range (ATR)
  • RCKT 0.27
  • KFS 0.38
  • MACD
  • RCKT 0.02
  • KFS 0.05
  • Stochastic Oscillator
  • RCKT 35.43
  • KFS 89.60

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

About KFS Kingsway Financial Services Inc. (DE)

Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.

Share on Social Networks: